Reduced expression of cyclooxygenase-2 in primary breast cancer.
Boneberg
Eva-Maria
EM
Legler
Daniel F
DF
Senn
Hans-Jörg
HJ
Fürstenberger
Gregor
G
D000730:Androstadienes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D000068579:Celecoxib; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D015536:Down-Regulation; D004359:Drug Therapy, Combination; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D011720:Pyrazoles / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000627:therapeutic use; D017211:Treatment Failure
D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; D000068579:Celecoxib; C056516:exemestane